Zilebesiran added to standard of care treatment for mild to moderate hypertension produced a clinically and statistically significant decrease in systolic blood pressure after three months.
Image credit: zinkevych | stock.adobe.com
Zilebesiran achieved the primary endpoint of the Phase II KARDIA-2 study (NCT05103332) evaluating Roche’s and Alnylam’s novel RNA interference therapeutic agent in the treatment of hypertension. The addition of zilebesiran to standard of care treatment for mild to moderate hypertension produced a clinically and statistically significant decrease in systolic blood pressure (SBP) after three months with an encouraging safety and tolerability profile, according to the study.1
“With twice-yearly dosing in combination with standard of care medication, zilebesiran has strong potential to sustain lower blood pressure and reduce the risk of stroke, heart attack and death that can result from inadequate treatment,” Roche Chief Medical Officer and Head of Global Product Development, Levi Garraway, MD, PhD, said in a press release. “We look forward to continuing the zilebesiran Phase II study program with Alnylam as we seek to provide transformative impact for millions of people living with uncontrolled hypertension.”1
According to the World Health Organization (WHO), approximately 1.28 billion adults from 30 to 79 years of age have hypertension worldwide, of whom an estimated 46% are unaware they have the condition and 42% are diagnosed and treated. Just 21% of adults with the condition are projected to have it under control, as hypertension is a significant cause of premature mortality with an estimated 10 million deaths worldwide each year.1,2
The subcutaneously administered zilebesiran targets angiotensinogen (AGT), which is the most upstream precursor in Renin-Angiotensin-Aldosterone System. This plays a significant role in regulating blood pressure and inhibiting this action has demonstrated antihypertensive effects.
The randomized, double-blind, placebo-controlled KARDIA-2 trial is analyzing the efficacy and safety of zilebesiran added to a standard of care in 672 adults with mild-to-moderate hypertension. Patients enrolled in the trial were randomly assigned to three different cohorts to receive open-label treatment with olmesartan, amlodipine, or indapamide as a protocol-specified background hypertension treatment during a run-in period lasting at least four weeks. After this point, patients were randomly assigned 1:1 to receive zilebesiran 600 mg or placebo plus their protocol-specified background hypertension treatment for six months.1
The results of the trial will be presented at the upcoming 2024 American College of Cardiology Annual Scientific Session from April 6-8, 2024. These results follow positive findings from the Phase II KARDIA-1 (NCT04936035) trial published in JAMA in February 2024.
In KARDIA-1, zilebesiran produced a clinically significant decrease in 24-hour mean SBP after three months, which translated to a placebo-subtracted decrease greater than 15 mmHg at both the 300 and 600 mg doses. Zilebesiran also achieved the key secondary endpoints of consistent and sustained decreases in SBP at six months, which supports quarterly or biannual dosing, according to Roche. Further, zilebesiran produced a potent and durable drop in serum AGT levels through six months with an encouraging safety and tolerability profile.3
“These early results indicate the potential for zilebesiran to achieve sustained blood pressure reduction with quarterly or biannual dosing,” Garraway said in a prior press release. “Also, these data underscore the potential of this investigational medicine to provide transformative impact for many people living with uncontrolled hypertension.”3
References
1. Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care. Roche. News release. March 5, 2024. Accessed March 6, 2024. https://www.roche.com/media/releases/med-cor-2024-03-05
2. World Health Organization. Hypertension. Webpage. Updated March 16, 2023. Accessed March 6, 2024. https://www.who.int/news-room/fact-sheets/detail/hypertension#:~:text=Overview,get%20your%20blood%20pressure%20checked.
3. Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease. Roche. News release. September 7, 2023. Accessed March 6, 2024. https://www.roche.com/media/releases/med-cor-2023-09-07
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.